Puhe BioPharma and Bayer Enter into Global License Agreement for Clinical Phase I PRMT5 Inhibitor PH001 Clinical Phase III National Investigator Conference Phase III Clinical Study of Class 1 new drug YK-029A Tablet developed by Suzhou Puhe Biopharma independently completed the First Patient Enrollment Breaking through the Difficult Target of Lung Cancer Treatment - Suzhou Puhe Biopharma PH001 (YK-029A) was approved by the National Medical Products Administration to carry out Phase III Clinical Trial Suzhou Puhe Biopharma reported on the progress of its self-developed project at the AACR Annual Meeting National Researchers Meeting for Phase III Clinical Research of Class I New Drug YK-029A Tablet independently studied and developed by Puhe Biopharma was successfully convened